Anti-Frizzled homologue 10 Antibody, Non-Fucosylated (BioBet-899ZP) (CAT#: BioBet-899ZP) Datasheet

FZD10

Fucosyl GM1

This gene is a member of the frizzled gene family. Members of this family encode 7-transmembrane domain proteins that are receptors for the Wingless type MMTV integration site family of signaling proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway. Using array analysis, expression of this intronless gene is significantly up-regulated in two cases of primary colon cancer.

FZD10; frizzled class receptor 10; Fz10; FzE7; CD350; FZ-10; hFz10; frizzled-10; frizzled homolog 10; frizzled family receptor 10; frizzled 10, seven transmembrane spanning receptor

Plasma membrane

Diseases associated with FZD10 include Fallopian Tube Serous Adenocarcinoma and Colorectal Cancer.

Its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and Signaling by GPCR.

Wnt protein receptor. Function (by similarity) in the classic Wnt/ -catenin signaling pathway. The classic Wnt/ -catenin signaling pathway leads to the activation of scatter proteins, the inhibition of GSK-3 kinase, the nuclear accumulation of -catenin, and the activation of Wnt target genes. A second signaling pathway involving PKC and calcium flux has been found in some family members, but it is not clear whether it represents a unique pathway or whether it can be integrated into the canonical pathway because of Wnt-mediated GSK-3 Kinase inactivation seems to require PKC. Both of these pathways seem to involve interaction with protein g. It may be involved in the formation of tissue morphology and/or the transduction of polarity information and cell-to-cell transmission in differentiated tissues (possibly).

1.Ubiquitinated by ZNRF3, leading to its degradation by the proteasome 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn48, Asn153, and Asn485

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-899ZP

Human

Human

OTSA101 is an antibody drug targets a novel tumor-specific antigen FZD10 (Frizzled homolog 10), used for cancer therapy, has conducted phase I clinical trial for synovial sarcoma, which is a type of soft tissue sarcoma.

Cancer

Cancer